GMDA News and Press, Gamida Cell Ltd. From 08/16/22

Today, we circle back on Gamida Cell Ltd., a small developmental company based in Israel for the first time since last November. The company has a key FDA approval pending which could shift the trajectory of the company and the stock. An investment analysis follows in the paragrap...

Image source: The Motley Fool. Gamida Cell Ltd. (NASDAQ: GMDA) Q2 2022 Earnings Call Aug 15, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript

Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Conference Call August 15, 2022, 08:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Julian Adams - CEO Ronit Simantov - CMO & Chief Scientific Officer Michele Korfin ...

Gamida Cell press release ( NASDAQ: GMDA ): Q2 GAAP EPS of -$0.31 misses by $0.02 . As of June 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $55.1M. Gamida Cell expects that its current cash, cash equivalents and investments will support...

- Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date set for January 30, 2023 - - Dosed first patient in company-sponsored Phase 1/2 study of cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse large B-cell...

Gamida Cell ( NASDAQ: GMDA ) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.29 (+61.8% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revisions and 2 downward. Fo...

-The company-sponsored Phase 1/2 study is evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas - Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy ...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 202...

AMTD IDEA ( AMTD ) +323% . 36Kr Holdings ( KRKR ) +70% . Quoin Pharmaceuticals ( QNRX ) +54% . Intelligent Living ( ILAG ) +40% . Getty Images Holdings ( GETY ) +24% stock rallies for second day, shares gain 19%. Innoviz ...

The U.S. Food and Drug Administration (FDA) granted priority review to Gamida Cell's ( NASDAQ: GMDA ) application seeking approval of stem cell therapy omidubicel to treat patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. The ...